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fold (VF) lesions and immediate implantation of esterified hyaluronic acid (EHA) in the surgical wound. In a previous
pilot study on 11 cases, we have shown an excellent tolerance of this bioimplant. The objectives are to confirm the in-
nocuity of the technique, to demonstrate the laryngeal and vocal evolution at short and long term, and to evaluate the
eventual positive impact of EHA implantation on the pliability of the superficial layer of the lamina propria (SLLP) and
on voice. This is a Prospective and comparative study on 83 patients suffering from various benign VF lesions. Thirty-
three patients were implanted with EHA, whereas 50 patients did not undergo implantation at the end of the microsur-
gical procedure.All patients undergo rigid laryngoscopy and microflap excision procedure under general anesthesia.
After freeing up of the Reinke’s space and creation of a mucosal microflap, a few fibers of EHA are inserted in the sur-
gical wound, before closure of the incision with fibrin glue. Serial laryngeal and vocal assessments are performed in all
patients using videostroboscopy (Wolff and Xion), perceptual and objective voice evaluation (MDVP software, Kay El-
emetrics), and phonatory function measurements (Aerophone II). Pre- and early postoperative means are compared by
analysis of variance. Delayed and long-term evolution of laryngeal and vocal data are compared by means of nonpara-
metric statistical methods. The longest follow-up in the implanted group is 4 years. Early postoperative results are sim-
ilar in both groups: a significant improvement of a majority of laryngeal and vocal data is observed after microsurgery. In
the long term, the two groups exhibit a different behavior: further improvement of voice, as an ongoing process, is only
observed in the EHA implanted group, together with improvement of some videostroboscopic characteristics. The non-
implanted group remains stable, with no further improvement of the voice quality obtained after microsurgery. Excellent
short- and long-term tolerance of EHA implantation is confirmed by this larger series. The use of EHA implant in micro-
dissected SLLP is safe and leads to good laryngeal and vocal outcomes in the treated patients. More interestingly, treated
cases exhibit a continuous improvement over a long period of time.
























Microsurgical procedures for benign VF lesions aim at improv-
ing the mechanical properties of the laryngeal vibrator. Restor-
ing a good pliability of the SLLP is essential. In normal VFs, the
SLLP, also called Reinke’s space, demonstrates favorable bio-
mechanical properties in terms of viscosity and stiffness thanks
to its cellular and molecular composition: few fibroblasts and
macrophages are surrounded by a very loose elastic and col-
lagen fibrous scaffolding and by interstitium molecules of the
extracellular matrix (ECM). Among these molecules, an equi-
librium between glycosaminoglycans, such as hyaluronic
Acid (HA) and decorin, and glycoproteins, such as fibronectin,
is necessary to maintain the ‘‘jelly-like’’ structure favorable to
vibration. HA is a high-molecular-weight glycosaminoglycan,
which is a normal component of the ECM everywhere in the hu-
man body. Because of its molecular structure and binding toted for publication December 31, 2008.
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116a large amount of water molecules, HA plays an important
role in determining the mechanical characteristics of the
SLLP.1 It influences the thickness of the lamina propria (LP):
men possess a thicker LP compared with that of women, and
this could be due to a three- to fourfold amount of HA in the
men’s LP.2 HA is necessary to maintain both optimal viscosity
and stiffness of SLLP. The removal of HA from the SLLP of hu-
man cadavers increases the tissue viscosity by two- to fourfold.3
Stiffness of the SLLP is also influenced by the amount of HA
present: removal of HA from the LP of adult human cadavers
decreases the stiffness of the VF cover by an average of 35%
but increases dynamic viscosity by 70%.4 Decreased stiffness
leads to unstable vibratory rate, whereas increased viscosity re-
duces pliability and, hence, mucosal cover traveling wave.
However, one of the very interesting characteristics of HA is
its influence on cell behavior and regulation of wound repair
and of morphogenetic events. Previous studies have shown
that HA influences collagen deposition: high levels of HA
reduce scar tissue formation with less fibrosis and less
contracture.5
This clinical work has been initiated because our 20 years’
experience in VF microsurgery has made us aware of the diffi-
culty in obtaining good pliability of the mucosal cover when
treating rigid and/or destructive lesions of the SLLP. Careful
microflap procedures for lesions such as very rigid nodules, ex-




























































































































cysts, and destructive lesions such as scars or sulci do not al-
ways succeed in restoring the pliability of the mucosal cover.
Because of the favorable and important biological and mechan-
ical roles played by HA in normal SLLP, we decided to inves-
tigate the use of a HA derivative bioimplant in selected surgical
cases. Previous animal studies showed that levels of HA are de-
creased in injured VF in the early days after injury, and the au-
thors believe that low HA level produces a less than optimal
environment for normal tissue regeneration and might contrib-
ute to formation of scar tissue.6 We hypothesized that increas-
ing HA in the wound would contribute to less collagen
deposition, less wound contracture, and possibly enhanced pli-
ability of the mucosal cover. Therefore, implantation of exoge-
nous modified HA in the surgical wound aims at playing the
role of a spacer between the elevated mucosal flap and the
deeper layers of the lamina propria and at modulating the heal-
ing and tissue repair processes by raising the local amount
wound aims at playing the of HA. The implant should be re-
sorbable in order to play only a temporary role. The implant
needs to create favorable healing conditions inside the SLLP,
and these conditions are fulfilled by an increased amount of
HA present in the surgical wound as well as by the creation
of a highly hydrated matrix favorable to the fibroblastic migra-
tion. We chose to use a well-known material initially dedicated
to ear, nose, and throat (ENT) surgery: the resorbable bioim-
plant is made of EHA, commercially known as MeroGel (Med-
tronic, Xomed, Jacksonville, Florida, USA). This implant is
usually used in sinus and otologic surgery to reduce adhesions
and scarring processes of the surgical bed.
In a previous pilot study on 11 cases, we have shown an ex-
cellent tolerance of this bioimplant made of EHA placed under
the mucosal flap, in the Reinke’s space, following a microsurgi-
cal procedure for a benign VF lesion: no adverse reaction was
observed during a time of follow-up comprising between 8
weeks and 19 months.7 Also, excellent pliability of the mucosal
cover is obtained postoperatively, particularly in cases where
mucosal stiffness was extremely important preoperatively.
The good results obtained in these first clinical experiences
needed to be confirmed by larger series and long-term follow-
up. The goals of the actual clinical study are as follows: 1) to
confirm the innocuity of the technique, 2) to demonstrate the la-













GRAPH 1. Serial follow-up of the implanted group. Each lozenge represen
are obtained for each patient.
FLA 5.0 DTD  YMVJ603_proof  30 Jaevaluate the eventual positive impact of EHA implantation,








This clinical study is prospective and comparative but not ran-
domized: selection criteria for implantation of EHA are used,
and surgical results obtained in the implanted group are com-
pared to those obtained in a nonimplanted group.
Eighty-three subjects are included in the study and undergo
a microsurgical treatment of benign VF lesions. Thirty-three
cases benefit from immediate implantation of a resorbable bio-
implant made of EHA in the surgical wound. Fifty cases do not
undergo implantation at the end of the microsurgical procedure.
Selection of cases for implantation is based on lesion character-
istics:
- Presurgical lesional absence of pliable SLLP: cases of ver-
geture, scar, subepithelial fibrosis, and sulcus
- Partial replacement of pliable SLLP by fibrotic tissue:
cases of rigid nodules, fibrotic polyps, and organized intra-
cordal hemorrhage, cysts surrounded by fibrosis
- Estimated higher risk of scar, due to the difficulty of dis-
section in some cases
The laryngeal and vocal data obtained in both groups are
compared.
All of the patients undergo a serial follow-up. The laryngeal
and vocal data obtained are carefully stored and submitted to
statistical analysis.
Graph 1 shows the follow-up of the implanted group. Each
lozenge represents a clinical evaluation. One preoperative eval-
uation and several postoperative ones are obtained for each
case. The number of postoperative evaluations depends on the
moment of microsurgery and on the patient’s compliance
with the appointments, the first treated cases very logically ex-
hibiting a larger number of postoperative checkups. The longest
follow-up is 4 years.
Subjects
The implanted group Q. The implanted group is composed of
33 patients (six edemas, five mucous cysts, four polyps, sixts a clinical evaluation: one preoperative and several postoperative ones
























































































301nodules, one sulcus, two scars, two subepithelial fibrosis, three
vergetures [two with mucosal bridge], and four open cysts) who
underwent a VF microsurgical procedure and implantation of
EHA between February 2003 and December 2006. Twenty-
three are females (70%), and 10 are males (30%). Twenty per-
cent had microsurgery on the left VF, 59% on the right VF, and
21% had a bilateral procedure. In 18%, CO2 laser was used for
the incision of the VF surface; the other cases were treated only
with cold instrumentation (Table 1).
Eight patients benefited from a bilateral implantation. The
first 11 cases included in our pilot study are part of this larger
series.
The nonimplanted group. The nonimplanted group is











Composition of the Implanted and Nonimplanted Group
Implanted Group
Subjects N¼ 33 N
Sex 23 women (70%)
10 men (30%)











Left (20%), Right (59%), bilateral (21%) L
N Preoperative mean
Grade (G) 32 2.593
Roughness (R) 32 2.562
Breathiness (B) 32 1.562
Asthenia (A) 32 0.562
Strain (S) 32 2.062
Instability (I) 32 2.500
Glottic closure 31 3.751
Left amplitude 12 1.841
Left mucosal wave 12 1.425








STD (F0) 33 9.818
NHR 32 0.158
Shimmer % 32 5.140
MPT (s) 18 10.226




Preoperative means of the laryngeal and vocal variables. Significant P values are
Abbreviations: STD, standard deviation; NHR, noise-to-harmonic ratio; MPT, max
FLA 5.0 DTD  YMVJ603_proof  30 JF
polyps, 7 nodules, and 13 pseudocysts) who underwent a VF
microsurgical procedure without subsequent implantation of
EHA between January 2004 and February 2007. Thirty-eight
are females (76%), and 12 are males (24%). Twenty-six percent
had microsurgery on the left VF, 34% on the right VF, 40% had
a bilateral procedure. In 20%, CO2 laser was used for the inci-
sion of the VF surface; the other cases were treated only with
cold instrumentation (Table 1).
The composition of the two groups (Table 1) is homogeneous
concerning the sex (Chi-square¼ 0.405, df¼ 1, P¼ 0.524), the
side of microsurgery (Chi-square¼ 5.45, df¼ 2, P¼ 0.06), and
the use of laser (Chi-square¼ 0.07, df¼ 1, P¼ 0.78).
The distribution of the clinical diagnosis of VF lesions (Table
















eft (26%), Right (34%), bilateral (40%) 5.45 (P¼ 0.06)
N Preoperative mean Student’s t test
50 2.020 3.55 (P¼ <0.001)
50 2.000 3.08 (P¼ 0.002)
50 1.260 1.54 (P¼ 0.12)
50 0.560 0.01 (P¼ 0.98)
50 1.400 2.45 (P¼ 0.01)
50 1.940 2.98 (P¼ 0.003)
47 3.487 0.98 (P¼ 0.32)
31 2.074 0.30 (P¼ 0.76)
32 5.065 3.27 (P¼ 0.002)
34 2.640 2.34 (P¼ 0.02)
32 6.606 4.94 (P¼ <0.001)
50 2.432 1.12 (P¼ 0.26)
50 5.896 0.43 (P¼ 0.66)
50 11.435 0.37 (P¼ 0.70)
50 0.157 0.01 (P¼ 0.98)
50 5.381 0.25 (P¼ 0.80)
37 11.780 1.03 (P¼ 0.30)
37 0.257 0.94 (P¼ 0.34)
36 10.711 2.26 (P¼ 0.95)
highlighted in bold Q13.
imum phonation time; MFR, mean flow rate.































































































































The commercially available EHA presents as a solid, fiber ma-
terial made of an EHA or HYAFF (Fidia Advanced Biopoly-
mers, Abano, Terme, Italy). The HA is a fermentation
product from Streptococcus Equii. The HAwas then esterified
on the carboxyl group of the glucuronic acid moiety of the poly-
mer with benzyl alcohol. The EHA implant used in this study is
HYAFF 11 (MeroGel), a 20 kDa molecule, in which 100% of
carboxyl groups of HA is esterified with benzyl alcohol and
is a registered trade mark of Medtronic Xomed, Jacksonville,
Fl. When placed in contact with the human body fluids, the im-
plant transforms into a highly hydrated gel. HYAFF polymers
are biodegradable and follow a well-characterized metabolic
pathway: first occurs the hydrolysis of the ester bond, releasing
free benzyl alcohol and soluble HA. The HA from the de-ester-
ification of HYAFF is indistinguishable from that of natural or-
igin and undergoes the same metabolic pathways: it is degraded
locally by binding to a CD44 receptor on the cell membrane of
fibroblasts and macrophages, cellular internalization, and fi-
nally destruction in the lysozome by hyaluronidase.1 The free
benzyl alcohol is degraded in the liver in benzoic acid and
then conjugated with glycin, to produce hippuric acid, which













































All patients undergo general anesthesia and routine laryngeal
intubation (tracheal tube size: 5.5–6.5). A direct laryngoscopy
is performed in all patients (Kleinsasser type laryngoscope,
Storz 8590C and 8590B). The microsurgical procedure is per-
formed under 403 magnification, with a 400 mm focal length
(Microscope Leica M655), which corresponds to a real magni-
fication of 103. The cordal lesion is treated either with cold in-
strumentation only (Bouchayer instrumentation from
MicroFrance and mini-microinstrumentation for laryngeal sur-
gery from Sto¨pler) or with CO2 Laser (Sharplan 40C).
All microsurgical procedures are done by the first author.
In both groups, the surgical procedures are identical, except
for the use of the bioimplant of EHA: a microflap procedure is
performed in all cases (both implanted and nonimplanted cases)
except in polyps of small size that are resected as a whole.
We describe here our microsurgical procedures: lesion treat-
ment, implantation of EHA (in the implanted group), and clo-
sure of the incision.
Lesion treatment. In the case of nodules, the procedure con-
sisted in a subepithelial cleaning of the nodular SLLP with no or
a minimal epithelial superficial resection to close the incision
perfectly.
In the case of a mucosal bridge associated to a vergeture, the
procedure is complex: the adherent epithelium is completely re-
sected during the creation of a mucosal flap, and then the muco-
sal bridge is sliced longitudinally to preserve the external half of
its mucosal cover. This allows to have at one’s disposal an ‘‘ac-
cessory’’ mucosal flap, to close the incision with less tension
and less concavity of the VF’s free edge.
For the patients with Reinke’s edema and pseudocysts, after






sacrifice too large an amount of mucosa in order to be able to
close the incision without any or minimal superficial defect.
Sessile polyps and intracordal hemorrhages are treated by
a subepithelial cleaning of the SLLP of all the fibrin and fibrotic
reaction. Polyps of small size or pediculated are more simply
resected as a whole.
Scars and subepithelial fibrosis are treated by an elevation of
the adherent epithelium from the ligament, creating a mucosal
flap under which EHA can be inserted.
Mucous and epidermoid cysts are resected by a mini-micro-
flap technique.
Implantation of EHA. The EHA implant is not an injectable
material but a solid material, macroscopically resembling cot-
ton-ball fibers. A few fibers of EHA bioimplant are taken
with the microforceps and gently arranged in Reinke’s space
between the ligament and the mucosal flap. The mucosal flap
is then redraped over the underlying EHA implant.
Closure of the incision. At the end of all microflap proce-
dures (both in implanted and nonimplanted patients), we use fi-
brin glue (Tissucol DUO 500, 0.5 mL, Baxter, Deerfield,
Illinois, USA). With a blunt dissector of Bouchayer, a drop of
‘‘glue’’ (human fibrinogen, fibronectin, plasminogen, and factor
XIII) is delicately placed in the incision, followed immediately
by a second drop of thrombin. A small external pressure is ap-
plied on the treated VF during 5 seconds, permitting a partial
polymerization of the glue. This allows a stable position of
the microflap and perfect closure of the incision.
Postoperative care. Postoperatively, all patients were ad-
vised to adhere to a vocal rest for 8 days. Preoperatively, they
received a 125 mg IV injection of methylprednisolone. Medical
postoperative treatment consisted of degressive oral methyl-
prednisolone, clobutinol hydrochloride, and paracetamol. The
implanted group received amoxy-clavulanate Qfor 1 week to pre-
vent infection of the implant.Laryngoscopic Examination
All patients undergo a general ENT clinical examination. For
each patient, one preoperative and several postoperative
video-laryngo-stroboscopies are obtained. We use a Wolff rigid
70 endoscope 4450.47 connected to a Wolff laryngostrobo-
scope 5052 or Xion’s EndoSTROB digital camera. Archiving
of the videostroboscopic views is done with an Olympus cam-
era Visera OTV-57 and video-recorder PanasonicAG-5700 or
with Xion’s DiVAS software. Topical anesthesia of the pharynx
(xylocaı¨ne 10% spray) is used. The patients are asked to sustain
an [i] at different pitches.
Amplitude of vibration and of mucosal wave as well as sym-
metry, inflammation, presence of a glottic gap, and of VF defor-
mation are the videostroboscopic findings that are taken into
account. Amplitude of vibration, mucosal wave, and glottic
gap are evaluated on analogic visual scales. For amplitude vi-
bration and mucosal wave, we use a bipolar scale: amplitude
of vibration is considered normal if noted at half the continuum,
increased to the right and decreased to the left. For mucosal
































































































































absent at the left end). It is also the case for glottic closure (com-
plete at the right end, absent at the left end).
Pliability of VF cover observed at the level of the lesion is the
most important videostroboscopic characteristic to be evaluated
pre- and postoperatively. In order to avoid confusion and statis-
tical bias, only the data of the microsurgically treated VFs are
included in the study.
In this prospective study, the microsurgeon is not blinded to
the situation of his patients. To reduce evaluation bias, video-
stroboscopic examinations are rated by two otolaryngologists
(one of them is the microsurgeon) and one experienced speech
therapist via group discussion and consensus.
Voice Evaluation
The voices are recorded in a soundproof booth on a Kay Eleme-
trics Computerized Speech Lab with a Kay Elemetrics head-
mounted microphone. The distance between the mouth and
the microphone is approximately 3 cm. Three sustained vowels
/a/ and five standardized texts for French are recorded at each
visit.
We use the GRBASI scale for the subjective evaluation of
the patient’s voice quality, after listening to the five produc-
tions of the standardized texts: G (grade), R (roughness), B
(breathiness), A (asthenia), S (strain), and I (instability).
Each item was quoted 0 (normal), 1 (light), 2 (moderate),
and 3 (severe). As for the videostroboscopic examinations,
evaluation is not performed in a blinded fashion, and a group
discussion is, therefore, performed by two otolaryngologists
and one experienced speech therapist, until consensus is
reached.
Software from Kay Elemetrics, Multi-Dimensional Voice
Program (MDVP) is used to obtain voice quality objective
data. Measurements of average fundamental frequency (Aver-
age F0), of highest and lowest fundamental frequency, standard
deviation of F0 (STD), phonatory F0-range (PFR), jitter %
(Jitt %), and noise-to-harmonic ratio (NHR) are derived from
3 second segments of each of the sustained /a/.
Phonatory Function Measurements
Measurements of maximum phonation time (MPT), intraoral
pressure, and mean flow rate (MFR) are realized by the use of
Aerophone II.
Preoperative Data
Mean values of both groups are compared by Student’s t test,
which shows some significant differences between the two
groups. Subjective voice ratings G, R, S, I are significantly
higher in the preoperative period, whereas the mucosal waves
and the right amplitude of vibration are significantly lower, in
the patients who will benefit from EHA implantation. All the
other obtained data show no significant difference in the preop-
erative period, between the implanted and the nonimplanted
group (Table 1).
Statistical Analysis
Early postoperative data: short-term outcome.
Early postoperative means obtained in both groups wereFLA 5.0 DTD  YMVJ603_proof  30 Jcompared by analysis of variance, (SPSS software, GLM Q
procedure, repeated measures): the dependent variable was
the data under study; the independent variables were the
group and the time of examination (preoperative or early







Delayed and Long-Term Outcome
Evaluation of laryngeal and vocal modifications with the pas-
sage of time after microsurgery is one of our goals, as we ex-
pect a different tissue remodeling in the two groups. Serial
follow-up is mandatory to demonstrate an eventual positive
effect of the implantation of EHA in the microdissected
SLLP.
The number and the moment of the postoperative evaluations
being variable from one patient to another, we decided to use
correlation criteria (nonparametric statistical analysis).
In this section, we decided not to take into account the imme-
diate postoperative results but the data obtained at least at the
second postoperative consultation and all the following ones.
Because of the highly variable moments of the postoperative
appointments at our Voice Clinic, we took into consideration
the number of days elapsed since microsurgery. We used the
correlation criteria of Kendall and Spearman to show a possible
correlation between the value of the different variables mea-
sured in our patients and the time elapsed since the VF micro-
surgery. The significance level is P < 0.05.RESULTS
Early Postoperative Results: Short-Term Outcome
The first postoperative data were obtained between 1 and 6
weeks after the VFmicrosurgery, although the patients were ad-
vised to present at the Voice Clinic 2 weeks after surgery.
An analysis of variance allows a between-time and between-
group comparison. The Fisher Snedecor F values and P values
are presented in Table 2. For each variable, two Fisher-Snede-
cor statistics compare (1) the pre- and the postoperative means
and (2) the pre- and postoperative means and group interaction.
The level of significance is P < 0.05. Significant P values are
highlighted in bold.
(1) All videostroboscopic and voice data are significantly
modified by the microsurgical procedure except NHR
(P¼ 0.09), Average F0 (P¼ 0.840), and Asthenia (A)
(P¼ 0.191). We observe a postoperative significant de-
crease in G, R, B, S, I, jitter %, PFR, STD of F0, MFR,
and of the subglottic pressure. A postoperative increase
in glottic closure (P < 0.001), MPT (P¼ 0.04), right am-
plitude and mucosal wave (P < 0.001), and left ampli-
tude and mucosal wave (P < 0.001) is observed.
(2) There is no difference between the two groups, regard-
ing the impact of the microsurgery, except for the left
mucosal wave, which is increasing more in the im-
planted group (P¼ 0.007) and shimmer %, which is de-






















F P value F P value
G 103.236 0.000 0.583 0.447
R 139.733 0.000 0.192 0.663
B 13.202 0.000 2.457 0.121
A 1.736 0.191 0.367 0.547
S 41.563 0.000 0.291 0.591
I 108.758 0.000 0.115 0.735
Glottic
closure
35.084 0.000 0.877 0.352
Left
amplitude




72.524 0.000 8.203 0.007
Right
amplitude




25.830 0.000 0.283 0.597
Average F0 0.041 0.840 0.163 0.687




5.277 0.024 0.677 0.413
F0 STD 4.711 0.033 1.593 0.211
NHR 2.937 0.328 0.968 0.328
Shimmer
%
10.807 0.002 4.006 0.049
MPT 4.265 0.045 0.042 0.839
MFR 7.420 0.009 0.401 0.530
Intraoral
pressure
8.975 0.005 0.043 0.837
For each variable, two Fisher-Snedecort statistics compare (1) the pre- and
the postoperative means and (2) the pre- and postoperative means and
group interaction. Level of significance is P < 0.05. Significant P values
are highlighted in bold.





















































































































CDelayed and Long-Term Outcome
Results are presented in Tables 3 and 4. Table 3 presents, in the
implanted group, the correlation coefficients observed between
each laryngeal and vocal variable and the number of days
elapsed since microsurgery. Ten significant correlations be-
tween time elapsed since microsurgery and the data under study
are present in the implanted group: G, R, I, glottic closure, left
and right amplitude of vibration, right mucosal wave, phona-
tory range of F0, STD F0, NHR. G, R, I, phonatory range of
F0, STD F0, and NHR are negatively correlated with time
elapsed since microsurgery: in other words, those variables con-
tinue to diminish in the delayed and long-term period only in
the implanted group. Glottic closure, bilateral amplitudes of vi-
bration, and right mucosal wave exhibit a positive correlationFLA 5.0 DTD  YMVJ603_proof  30 Jawith the time elapsed: they keep increasing in the implanted
group.
Table 4 presents, in the nonimplanted group, the correlation
coefficients observed between each laryngeal and vocal vari-
able and the number of days elapsed since microsurgery. The
only datum showing a positive correlation with the time elapsed
is the left mucosal wave. All the other variables remain at a sta-
ble value, obtained after microsurgery: there is no further evo-





FDISCUSSIONBefore discussing the obtained results, we would like to make
some comments on the limitations and strengths of the study de-
sign: both of these are intimately linked to the clinical (and not
experimental) setting of this work.
The first limitation of this study is the absence of randomiza-
tion: we used careful selection criteria to determine whether or
not to place an implant inside SLLP’s surgical wound at the end
of the procedure. This explains the disparity of the VF lesions’
diagnosis between the implanted and nonimplanted group: the
use of esterified HA is limited to VF lesions associated with sig-
nificant diminution of pliability of the VF cover. In these 33
cases, fibrotic tissue response was always observed inside the
SLLP, at the time of surgery. This was especially obvious in
cases with a partial or total absence of SLLP, like in sulcus,
scar, subepithelial fibrosis, and vergeture. In the implanted
group, nodules were rigid and fibrotic compared to the nonim-
planted group nodules, which were more flexible and pliable.
The polyps treated with subsequent implantation of EHA
were sessile and associated with occupation of SLLP by fibrin
and fibrosis sequellae of diffuse intracordal hemorrhage. The
treated cysts were surrounded by thick fibrotic response, mak-
ing their dissection difficult, and in the six edemas implanted
with EHA, pouches of edemas were surrounded by thick fi-
brotic septae. These very different SLLP characteristics (ab-
sent/rigid in the implanted group, excessive/highly pliable in
the nonimplanted group) are the driving justification for using
or not using the EHA implant and explain the inhomogeneity
of the preoperative diagnosis in the two groups. In such a clini-
cal work evaluating an innovative microsurgical procedure,
a prospective approach needs a careful selection of patients
and of the material implanted. This is a necessity because of
the clinical and ethical issues. Our work has indeed been ap-
proved and supervised during 4 years by a thesis committee
composed of seven members of our faculty.
A second limitation is due to a nonblinded assessment of the
stroboscopic and subjective voice evaluations. Some explana-
tions can be given for this bias: the microsurgeon cannot be
blind to the clinical situation of his or her patients, and because
of the obvious presence of the VF lesion before surgery, the two
other examiners cannot blindly evaluate the first postoperative
videostroboscopy.
Finally, a third limitation is the existence of a postoperative
antibiotic treatment only in the implanted group: we were con-
cerned by the possibility of infection of the bioimplant placed in










Long-Term Outcome of the Implanted Group: Correlation Coefficients of Kendall and of Spearman, Between the Time
Elapsed Since Microsurgery and the Value of the Laryngeal and Vocal Variables
Laryngeal and Vocal Variables
Implanted Group
Kendall Correlation Coefficient Spearman Correlation Coefficient
Coefficient Value N P Value Coefficient Value N P Value
G 0.219 72 0.01 0.291 72 0.013
R 0.208 72 0.02 0.267 72 0.02
B 0.068 72 0.46 0.10 72 0.39
A 0.06 72 0.50 0.07 72 0.52
S 0.07 72 0.38 0.11 72 0.34
I 0.19 72 0.03 0.26 72 0.02
Glottic closure 0.20 72 0.01 0.29 72 0.01
Left amplitude 0.32 28 0.02 0.42 28 0.02
Left mucosal wave 0.20 28 0.15 0.27 28 0.16
Right amplitude 0.35 49 0.001 0.48 49 0.000
Right mucosal wave 0.29 48 0.006 0.39 48 0.006
Average F0 0.49 73 0.49 0.07 73 0.53
Jitter % 0.13 73 0.09 0.20 73 0.07
F0 phonatory range 0.20 73 0.01 0.29 73 0.01
STD of F0 0.186 73 0.02 0.26 73 0.024
NHR 0.18 72 0.03 0.25 72 0.03
Shimmer % 0.08 73 0.29 0.13 73 0.27
MPT 0.02 46 0.79 0.04 46 0.78
MFR 0.08 44 0.41 0.11 44 0.44
Intraoral pressure 0.11 42 0.29 0.18 42 0.23
Significance level is P < 0.05. Significant correlations are highlighted in bold.


























































































































CDespite these limitations, the qualities of this clinical studyare its prospective nature on quite a large group of patients (if
compared with other studies on microsurgical results), the in-
clusion of long-term follow-up, an extensive evaluation of the
cases, and, most importantly, an original nonparametric statis-
tical analysis of the data obtained in the long term. This non-
parametric analysis performed outside the immediate
postoperative period aims at showing a relation between the
value of the different variables and the passage of time. Because
of clinical conditions (after surgery, the included patients are
never examined at the same period of time), an analysis of var-
iance is inappropriate: artificial temporal grouping of data
would be inconclusive. We, therefore, decided to use correla-
tion criteria and to take into account the precise number of
days elapsed since the VF microsurgery. This process allows
us, although in clinical conditions and serial follow-up, to over-
come the difficulty of the time homogeneity of the evaluations:
no predefined period of observation gives us the opportunity to
evaluate a large number of statistically useful data and observe
interesting microsurgical results never described before.
Early Postoperative Results
The early postoperative results show expected modifications of
laryngeal and voice data in both groups. Glottic closure, ampli-
tude of vibration, and mucosal waves significantly increase
after microsurgery, whereas quality of voice improves signifi-
cantly at the subjective rating on the GRBASI scale. FrequencyFLA 5.0 DTD  YMVJ603_proof  30 Jinstability (jitter %, PFR, STD of F0) and intensity instability
(shimmer %) regress significantly in both groups. Aerodynamic
data are also clearly modified by VF microsurgery: MPT in-
creases, whereas intraoral pressure and MFR significantly di-
minish. These results are in accordance with results reported
in the literature. A significant decrease in the grade of hoarse-
ness (G), roughness (R), breathiness (B), jitter, shimmer, and
noise energy is observed 2 weeks after microsurgery for nod-
ules and polyps.8 Another study on a series of 50 patients
with various benign VF pathologies (mainly polyps) shows sig-
nificant lowering of MFR but not of MPT after VF microsur-
gery; the authors insist on the importance of improving
mucosal wave and amplitude of vibration to improve voice.9
In a small series of 20 patients treated for Reinke’s edema, a sig-
nificant decrease in shimmer % is obtained but no significant
lowering of jitter %, subglottic pressure, or MFR.10
In the immediate postoperative period, the observed results
have to take into account the viscoelastic properties of the im-
planted esterified HA and the ongoing healing process. Im-
planted patients improve their ratings with the same intensity
as that of the nonimplanted patients, although they exhibit
worse preoperative voice and stroboscopic ratings. Pliability
of the VF cover is good in implanted patients. This is an ex-
tremely important finding, because it is the first time, to our
knowledge, that exogenous HA is used in the vibrating cover
of the human VF: the implant is placed inside the microdis-









Long-Term Outcome of the Nonimplanted Group: Correlation Coefficients of Kendall and of Spearman, Between the Time
Elapsed Since Microsurgery and the Value of the Laryngeal and Vocal Variables
Laryngeal and Vocal Variables
Nonimplanted Group
Kendall Correlation Coefficient Spearman Correlation Coefficient
Coefficient Value N P value Coefficient Value N P Value
G 0.001 60 0.98 0.002 60 0.99
R 0.05 60 0.62 0.06 60 0.63
B 0.06 60 0.51 0.08 60 0.51
A 0.009 60 0.93 0.01 60 0.90
S 0.06 60 0.54 0.08 60 0.53
I 0.11 60 0.25 0.14 60 0.28
Glottic closure 0.11 59 0.21 0.17 59 0.18
Left amplitude 0.18 40 0.10 0.26 40 0.09
Left mucosal wave 0.31 42 0.009 0.41 42 0.006
Right amplitude 0.07 45 0.51 0.10 45 0.48
Right mucosal wave 0.09 43 0.44 0.12 43 0.44
Average F0 0.13 57 0.14 0.20 57 0.13
Jitter % 0.03 57 0.70 0.04 57 0.74
F0 phonatory range 0.02 57 0.83 0.02 57 0.83
STD of F0 0.04 57 0.59 0.08 57 0.55
NHR 0.01 57 0.88 0.02 57 0.86
Shimmer % 0.06 57 0.45 0.10 57 0.45
MPT 0.01 50 0.87 0.01 50 0.90
MFR 0.03 50 0.69 0.05 50 0.70
Intraoral pressure 0.008 48 0.93 0.004 48 0.97
Significance level is P < 0.05. Significant correlations are highlighted in bold.



























































































































Tthe importance of the viscoelastic properties of biomaterials for
VF procedures. If the implant is too viscous or too rigid, it will
lead to lack of pliability of the VF cover, lack of vibratory
movement, and poor voice results, which is not, fortunately,
what we observe with EHA. Comparison of the viscoelastic
properties of the human VF cover and of that of various bioma-
terials (micronized alloderm; Cymetra, Lifecell corp, Branch-
burg, New Jersey, USA), Teflon (Mentor Inc, Hingham,
Massachusetts, USA), Gelfoam (Upjohn Co, Kalamazoo,
Michigan, USA), and collagen (Zyplast Collagen corporation,
Palo Alto, California, USA) have shown that all these biomate-
rials are muchmore rigid and viscous than the VF cover and are,
therefore, not usable inside the mucosal cover.13–16 By contrast,
rheologic and animal studies have shown that biomaterials
made up of modified HA exhibit favorable viscoelastic proper-
ties that make them good candidates for a very superficial use in
the VF’s lamina propria.3,4,11,13,14,16,17
The potential risk of impaired VF pliability due to the im-
planted biomaterial explains our choice of first developing
this technique in cases in which rigidity of the mucosal cover
and tissue fibrosis were pre- and peroperatively evident.
According to the manufacturer of MeroGel, the implant dis-
solves in 2 weeks in the nose and in 6 weeks in the middle ear.
From the observation of the laryngeal image, we interpret the
disappearance of a slight convexity of the treated VF observed
in three of our cases as the probable resorption of the inserted
EHA implant: it would mean that 3 to 4 weeks are necessary
for the resorption of the implant. No previous observation isFLA 5.0 DTD  YMVJ603_proof  30 Jareported on the use of modified HA in the subepithelial portion
of the human VF, all other studies reporting results on deep in-
jections of hyaluronan-based biomaterials for the treatment of
glottic insufficiency,12,18,19 the authors observing good video-
stroboscopic evolution and the absence of adverse effects. Ac-
cording to a recent study, some hyaluronan-based biomaterials
exhibit viscoelastic properties that can make them suitable for
superficial injection in the VF: Hylaform and Restylane, which
are dermal fillers used in the treatment of wrinkles and skin
scars, were tested in vitro for their viscosity and elasticity,
and they showed slightly higher values compared with those
of human SLLP. Hylaform was less viscous than Restylane
and, according to the authors, a possible bioimplant for super-
ficial use in the VFs.13
Delayed and Long-Term Results
The delayed and long-term results have to be discussed while
taking into account tissue healing and remodeling processes
taking place inside the SLLP. In that time frame, the resorbable
EHA has been removed from the SLLP by the natural degrada-
tion processes. The data show a very different behavior of the
implanted group in comparison with the nonimplanted one:
the implanted patients exhibit a continuous improvement of
10 laryngeal and voice parameters, whereas the nonimplanted
group modifies only one stroboscopic parameter. This is
a very important finding for two reasons. First, serial observa-
tions over several years of follow-up have never demonstrated
continuous improvement after VF microsurgery. The publishednuary 2009  8:59 pm  ce




























































































































studies rather evaluate the immediate postoperative results and
long-term stability of the microsurgically obtained results.12,20
Second, this continuous improvement over time is observed
only in the patients implanted with EHA.
Does that long-term evolution depend on a slower improve-
ment of the implanted patients because of worse preoperative
laryngeal conditions? This could partly explain the improve-
ment of G, R, S, I, and of right amplitude and mucosal wave,
which were significantly worse preoperatively in the implanted
group. However, this explanation is insufficient for the contin-
uous improvement of the other measured variables and espe-
cially the objective voice variables. Moreover, all the
improving laryngeal and vocal variables exhibit the same early
postoperative behavior in both groups. The nonimplanted group
reaches its acme of improvement in the early postoperative pe-
riod, and no further evolution is observed. On the other hand,
the implanted group exhibits a peculiar evolution, with a slow
improvement of 10 voice and laryngeal variables with the pas-
sage of time. We think that this is due to the improvement of tis-
sue mechanical properties: a more favorable tissue remodeling
of the SLLP in the presence of EHA implanted in the surgical
wound is a possible explanation. Positive effects of HA on heal-
ing are well known and have been extensively studied in skin
tissue repair. Scarless healing of skin is observed in fetal heal-
ing, and this regeneration-like tissue repair is thought to be
linked to the very high concentration of HA in the amniotic
fluid, for a prolonged period of time.21 Both in vitro and in
vivo (animal and human) studies on skin tissues have been con-
ducted. In vitro, contraction by fibroblasts was significantly re-
duced when concentration of HA was >1 mg/mL.22 In vivo, as
early as the seventies, application of high-molecular-weight
(>13 1,000,000 Da) purified HA to skin incisions, in different
animal species, decreased granulation tissue and fibrosis.23
Subsequent studies have demonstrated that HA provides a ben-
eficial effect on the quality of the scar tissue.5,24 The actions of
HA in the ECM are both mechanical and biological. The mol-
ecule binds to a large amount of water molecules, maintaining
the volume of the extracellular space and acts as a molecular
sieve capable of excluding large molecules such as fibrinogen
and of modifying chemotactic gradients. HA plays a wide range
of biological roles, regulating several cellular activities such as
cell attachment, cell proliferation, cell migration, and cell dif-
ferentiation. This wide range of activities results from the exis-
tence of a large number of HA-binding proteins (termed
hyaladherins) that exhibit large differences in their cellular lo-
calization, affinity, specificity, and tissue expression.25 These
hyaladherins are present on the cell surface of fibroblasts, neu-
trophils, activated T cells, and macrophages. HA is, therefore,
capable of modifying the activity of those cells and to, thereby,
reduce inflammation and subsequent collagen deposition. In
skin tissue repair, favorable effects of exogenous HA on healing
and scarring processes are achieved when the molecule is main-
tained at the wound site for a prolonged period of time, at least
during several days.5 As stated before, from the videostrobo-
scopic data obtained in the immediate postoperative period,
we suggest that our implant stays in place several weeks, which






of implants in skin tissue repair studies. Hardly anything is
known on human VF’s SLLP healing, remodeling, and scarring
processes, and especially nothing is known on the actual levels
of HA in the wound site. It is, therefore, impossible to guess
which time of residence of the implant is needed to favor better
healing conditions in the microdissected SLLP. The desired
time of residence of the implant could even be very different,
depending on the type of pathology: we hypothesize from our
clinical observations that the residence time is probably insuf-
ficient in cases of very deeply altered SLLP such as scars and
vergetures. Modulation of healing processes by HA in these
cases might also be less efficient because of the absence of re-
sidual cellular and molecular environment in the altered SLLP,
knowing that the action of HA is partly due to cell response,
which is context-specific.26 In a recent study, injection of
cross-linked HA (Restylane) in the dermis of photo-damaged
human skin stimulated the collagen synthesis by the dermal fi-
broblasts, partially restoring the lost ECM components.27 Time
of residence of the exogenous HA in the wound is not the only
important factor: different parameters of wound repair, like
wound contraction and angiogenesis, are influenced by the mo-
lecular weight of the HAmolecule. High-molecular-weight HA
(>1,000,000 Da) accelerates wound contraction and reduces
angiogenesis.28 Conversely, low-molecular-weight HA has
a stimulating effect on angiogenesis as demonstrated in various
animal models.29 The EHA implant used in our study is a low-
molecular-weight modified HA, only 20,000 Da. We never
observed any permanent hypervascularization in any of our pa-
tients, but it is of course a clinical evaluation of the laryngeal
image, without any histological analysis. A micro-angiogenesis
effect is thus still possible.
Only one case of important and long-lasting inflammation
was observed, in a patient treated for mucous cyst: fibrinous
and rigid VF is visible at the first postoperative evaluation.
The patient did not comply with vocal rest and did not take
the prescribed medications in the postoperative period. We sug-
gest that the unfavorable evolution is due to infection of the
wound. It took several weeks to observe the closure and healing.
Inflammation and decreased pliability of the mucosal cover of
the treated VF are still observed 8 months after microsurgery.
From our data, we can conclude that EHA implantation is
well tolerated in our series.
In a dermatologic survey on the safety of injectable non-an-
imal modified HA, published in 2004, the incidence of hyper-
sensitivity is reported to be around 0.6%, and the authors
conclude a high safety level of the HA filler in dermatology.
The authors stress that no skin testing is necessary before the
injection, because the preparation, theoretically, does not con-
tain any protein. The study described one case of hypersensitiv-
ity reaction lasting more than a year.30
In the field of laryngology, cross-linked hyaluronan has been
used in augmentative surgery as an injectable material in pa-
tients suffering of glottic insufficiency, with very good results
on videostroboscopic parameters and absence of adverse side
effects.12,19 The authors noted a few patients with early signs
of inflammation (within a week after injection), but all cases re-
solved without sequellae within 30 days. In our series, we didanuary 2009  8:59 pm  ce
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1089observe a very transient redness of the implanted region of the
SLLP in two cases, which resolved in a few weeks. From our



























From our several years’ experience of the use of EHA in the mi-
crodissected SLLP at the end of a microsurgical procedure, we
conclude that the use of the implant is safe and leads to good
laryngeal and vocal outcomes in the treated patients. More in-
terestingly, treated cases exhibit a continuous improvement
over a long period of time. Additional clinical studies are
needed to obtain a clear view on the benefits of the use of mod-
ified HA inside the microdissected SLLP at the end of a micro-
surgical procedure like prospective studies in large groups of
well-defined benign VF lesions. In addition, after this prospec-
tive work, and because of the good functional results as well as
the absence of adverse effects of the intra-SLLP implantation,
randomized studies could be undertaken.
The observations reported here are encouraging and raise
many questions on the lifetime of HA implants in the SLLP,
on their viscoelastic properties and modifications over time,
on the modulation of healing and, possibly, on the regeneration
of the SLLP.
The answers to those questions need thorough investigations
in vitro and in vivo to improve our understanding of the biolog-
ical maintenance of the human SLLP, both in normal and path-
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